Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Dr Tina J Hieken
Mayo Clinic, Rochester, MN, USA
Dr Tina Hieken is a fellowship-trained surgical oncologist and professor of surgery at the Mayo Clinic, Rochester, MN, USA, where she is also medical director for quality and accreditation for the Mayo Clinic Comprehensive Cancer Center. read more
Dr Hieken serves as chair for the American College of Surgeons Cancer Surgery Standards Program and on several national committees and editorial boards. Her research interests are translational and include applications of molecular signatures in cancer and cancer-risk prediction and prevention; functional characterization of the endogenous microbiomes in health and disease; neoadjuvant immunotherapy and drivers of immune response; and surgical innovation, including the application of technological advances and minimally invasive techniques to deliver patient-focused surgical oncology care. Her research funding includes awards from the Stand Up to Cancer/American Association for Cancer Research Catalyst Program, the Breast Cancer Research Foundation and National Cancer Institute.
Dr Tina J Hieken discloses: Grants/research support from Genentech and SkylineDx.
Prof. Piotr Rutkowski
Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
Prof. Piotr Rutkowski is professor of surgical oncology at the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Poland. Prof. Rutkowski is head of the Department of Soft Tissue/Bone Sarcoma and Melanoma, and plenipotentiary of head director of the Institute for National Oncological Strategy and Clinical Trials. read more
Prof. Rutkowski has participated in several investigator-driven trials in melanoma and sarcoma. He is a reviewer for several international scientific journals, as well as a member of the editorial board of Annals of Surgical Oncology and European Journal of Surgical Oncology.
Prof. Rutkowski is an active member of the European Organisation for Research and Treatment of Cancer (EORTC) Melanoma Group and EORTC Soft Tissue and Bone Sarcoma Group. He has chaired the EORTC Board Local Treatment Subcommittee and Membership Committee. He is a member of several Polish and international scientific societies (president of Polish Oncological Society, board member of Polish Society Surgical Oncology, ex-member of the board of directors of the Connective Tissue Oncology Society, member of Membership Advisory Committee of the American Society of Clinical Oncology [ASCO], and member of the Global Curriculum Committee of the European Society for Medical Oncology [ESMO]).
Prof. Rutkowski has authored or co-authored over 500 scientific papers in Polish and international journals, and is co-author of national and international recommendations for sarcoma and melanoma. He works very closely with national patient advocacy groups for gastrointestinal stromal tumours (GIST)/sarcoma and melanoma, coordinating the Polish Sarcoma Group, and is chairman of the Melanoma Academy in Poland, president of the Council of Agency of Medical Research, and chair of the Task Group of Ministry of Health, Poland for National Oncological Strategy.
Prof. Piotr Rutkowski discloses: Advisory board or panel fees from Bristol Myers Squibb, Genesis Pharma, Medison Pharma and MSD.
Dr Teresa Amaral
Tübingen University, Tübingen, Germany
Dr Teresa Amaral is head of the Skin Cancer Clinical Trials Center and lecturer at Tübingen University in Tübingen, Germany, Porto University and Beira Interior University, Portugal. Dr Amaral has been responsible for the Skin Cancer Center biobank in Tübingen since 2018 and has been head of the Skin Cancer Clinical Trials Center in Tübingen since 2021. read more
Dr Amaral has been a board-certified specialist in internal medicine, haematology and oncology through the German Medical Association since 2021. Her research primarily focuses on predictive biomarkers for systemic therapy in advanced melanoma and prognostic and predictive biomarkers in early-stage melanoma.
Dr Amaral has served as the chair of the European Society for Medical Oncology (ESMO) Young Oncologists Committee, and is currently a member of the ESMO Melanoma and Other Skin Tumours Faculty. She is a subject editor for the guidelines on melanoma and other skin cancers. Dr Amaral has been chair of the ESMO Leadership Development Committee since January 2023 and serves as an ESMO Council Member. She is an author or co-author on over 50 papers in peer-reviewed journals, including European Journal of Cancer, Journal of Clinical Oncology, Nature Medicine and ESMO Open.
Dr Teresa Amaral discloses: Advisory board or panel fees from Delcath and Philogen. Consulting fees from Bristol Myers Squibb, CeCaVa, MedTrix, MSD, NeraCare, Novartis and Pierre Fabre. Grants/research support from Agenus, AstraZeneca, BioNTech, Bristol Myers Squibb, HUYA Bioscience, iFIT, Immunocore, IO Biotech, MSD, NeraCare, Novartis, Pascoe, Pfizer, Philogen, Regeneron, Roche, Sanofi and SkylineDx.
